This could be fun when Europeons see this:
SSP who wrote (81523)
From: lindao
Thursday, Mar 8, 2001 7:37 PM
View Replies (2) | Respond to of 81555
Vitro Files Patent: May Prevent 'Mad Cow Disease' Spread to Biotech Products
Jump to first matched term
A STORY WITH SIZZLE!
LITTLETON, Colo., March 8 /PRNewswire/ -- Vitro Diagnostics, Inc. (OTC Bulletin
Board: VODG) announced today that it has filed a patent application with the United States
Patent and Trademark Office entitled "Defined Medium for the Culture of Human Cells."
This filing seeks patent protection for the Company's specially formulated, liquid cell culture
medium, which can be used to grow human cells in a manner that ensures their protection
against infection by "Mad Cow Disease." Biotechnology scientists often grow their
product-producing cells in a medium containing fetal bovine serum. With the
ever-increasing spread of "Mad Cow Disease," there is a high demand for media
that can guarantee that "Mad Cow Disease" would not be spread via therapeutic
interventions.
The Company has derived a specialty medium that is optimal for the proliferation of human
cells in cell culture. This medium is serum-free and contains clearly defined components
that are available from non-animal sources. This medium is necessary for production of
biopharmaceutical materials that originate from cultured human cells. Current FDA
guidelines suggest the use of defined, serum-free culture medium to produce biological
therapeutic products because of concerns regarding the introduction of contamination into
drug products.
The Company's product pipeline includes various forms of purified FSH and related
products for use in the treatment of infertility. A plan for the approval of its first product,
VITROPIN(TM), is under review by the FDA. VITROPIN(TM) is a highly purified form
of urinary FSH produced through the Company's patented method. Additional
patent-pending products include VITROPIN-C(TM), custom FSH that reduces side effects
of current products, VITROPIN-V(TM), a breakthrough FSH product produced from a
proprietary immortalized cell line, and VITROJECT(TM), a novel drug injection device for
administration of FSH and other drugs.
VITROCELL-X(TM) is the designation of a series of immortalized cell lines in which "X"
represents the organ from which the cell line was derived, and each of which produces
"natural therapeutic" products. For example, "VITROCELL-PG(TM)" is a cell line derived
from the human pituitary gland that produces FSH. VITROCELL-X(TM) cell lines are
produced by the Company's proprietary platform technology method, VITROCELL-X(TM)
CELL IMMORTALIZATION TECHNOLOGY, which uses the controlled
over-expression of specific genes to produce cellular immortalization.
The newly discovered medium that is the subject of the recently filed patent application
would be used in the production of "Naturally Pure Therapeutics"(TM) from immortalized
human cells.
Additional information may be accessed through the Company's web site at
www.vitrodiag.com |
